FINWIRES · TerminalLIVE
FINWIRES

$REGN

34 stories mentioning REGN

Every FINWIRES story that references REGN, newest first.

Research

Research Alert: CFRA Lowers Rating On Shares Of Regeneron Pharmaceuticals, Inc To Hold From Buy

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Shares of Regeneron are down more than 10% today after the company announced on Friday evening, after market close, that the Phase 3 study of fianlimab did not achieve a statistically significant primary endpoint in progression-free survival (PFS). The advanced clinical trials were assessing fianlimab in combination with cemiplimab (PD-1 inhibitor) for first-line unresectable or metastatic melanoma, a skin cancer that has spread beyond its original location versus pembrolizumab (PD-1 inhibitor), which is Merck's blockbuster oncology drug, Keytruda. While the company aims to present detailed data at an upcoming medical meeting, the release reflects diminished prospects for what had been anticipated as a highly promising treatment with a blockbuster potential, in our view. We lower our target price to $650 from $846, based on 12.4x our 2027 EPS estimate, a discount to REGN's 10-year historical forward P/E average. We retain our 2026 EPS estimate at $45.59 and our 2027 EPS estimate at $52.62.

$REGN
Asia Markets

US Equity Indexes Off Session Lows as Trump Postpones Iran Attack

US equity indexes closed mixed, albeit off session lows, as President Donald Trump agreed to delay a "large-scale" attack on Iran on Tuesday at the request of leaders from the Middle East negotiating with Tehran.The Nasdaq Composite fell 0.5% to 26,090.73, with the S&P 500 down less than 0.1% to 7,403.05 on Monday. The Dow Jones Industrial Average rose 0.3% to 49,686.12. Technology and industrials led decliners at the close. Energy, financials, and consumer staples were among the top gainers.President Trump will "hold off" on a Tuesday plan to attack Iran, citing a request from Qatar, Saudi Arabia, and the United Arab Emirates as he said negotiations to end the war grow more "serious," CNN reported Monday. "This Deal will include, importantly, NO NUCLEAR WEAPONS FOR IRAN," Trump was cited as saying.Trump also instructed his leadership "to be prepared to go forward with a full, large-scale assault of Iran, on a moment's notice" if a deal isn't reached, according to the president's Truth Social post.Meanwhile, Iran offered an updated peace proposal, which the White House adjudged lacking meaningful improvement over the previous offer, rendering the latest version insufficient to reach a deal to end the war, a senior US official and a source briefed on the issue told Axios.Separately, the US has agreed to release a quarter of Iran's frozen funds - totaling tens of billions of dollars - held in foreign banks, a senior Iranian source told Reuters. Washington has shown more flexibility in allowing Iran to continue some peaceful nuclear activity under the supervision of the International Atomic Energy Agency, the source told the news agency.West Texas Intermediate crude oil futures climbed 1% to $106.48, and Brent crude futures fell 0.4% to $108.83.US Treasury yields slipped after trading mixed earlier in the session. The 10-year was little changed at 4.59%, the highest in about a year. The 30-year rate was steady at 5.13%, the strongest level since 2007.In precious metals, gold futures rose 0.2% to $4,568.8, and silver futures climbed 0.5% to $77.97, clawing back all declines from earlier in the session.In economic news, the National Association of Home Builders' monthly housing market index rose to a reading of 37 in May from 34 in April, compared with expectations for a 34 print in a survey compiled by Bloomberg. The index was above the 34 print reported a year earlier.The New York Federal Reserve's services index improved to minus 5.8 in May from minus 14.0 in April, the highest level since January 2025. The index is the first services sector reading for May and suggests a slower contraction.In company news, NextEra Energy (NEE) and Dominion Energy (D) agreed to merge in an all-stock deal to create the world's largest regulated electric utility. Shares of Dominion jumped 9.4%, the second-biggest gainer on the S&P 500.Regeneron Pharmaceuticals' (REGN) miss on the fianlimab trial may lead some investors to question the company's broader strategy and execution, RBC Capital Markets said. Regeneron's shares sank 9.8%, the steepest decline on the S&P 500 and the Nasdaq.

Dow JonesNasdaq CompositeS&P 500$D$NEE$REGN
International

US Equity Markets Mixed as Investors Weigh Reports of Iran's Updated Peace Proposal

US equity indexes were mixed on Monday as investors weighed reports of an updated peace proposal from Iran.* Iran has offered an updated proposal, which the White House sees as lacking meaningful improvement over the previous offer, rendering the latest version insufficient to reach a deal to end the war, a senior US official and a source briefed on the issue told Axios.* The National Association of Home Builders' monthly housing market index rose to a reading of 37 in May from 34 in April, compared with expectations for a 34 print in a survey compiled by Bloomberg.* The New York Federal Reserve's services index improved to minus 5.8 in May from minus 14.0 in April, the highest level since January 2025.* June West Texas Intermediate crude oil rose $0.73 to settle at $106.15 per barrel, while July Brent crude, the global benchmark, was last seen down $0.02 at $109.18.* NextEra Energy (NEE) and Dominion Energy (D) agreed to merge in an all-stock deal to create the world's largest regulated electric utility. Shares of Dominion were up about 9.3%, the biggest gainer on the S&P 500.* Regeneron Pharmaceuticals' (REGN) miss on the fianlimab trial may lead some investors to question the company's broader strategy and execution, RBC Capital Markets said in a note. Regeneron's shares fell nearly 10%, the steepest decline on the S&P 500 and the Nasdaq.

Dow JonesNasdaq CompositeS&P 500$D$NEE$REGN
Wire

Top Midday Decliners

Regeneron Pharmaceuticals (REGN) said two dose levels of fianlimab in combination with cemiplimab, evaluated as a first-line treatment in unresectable locally advanced or metastatic melanoma, failed to meet a primary endpoint in its phase 3 trial.The company's stock dropped 10% as intraday volume topped 2.17 million shares versus the daily average of about 685,000.Seagate Technology's (STX) shares slumped 9.7% after CEO Dave Mosley said building new factories to meet demand would "take too long."Intraday volume topped 3.05 million shares versus the daily average of about 3.97 million.Air Global's (AIIR) shares fell 23% in their Nasdaq debut with volume of about 29,500.Price: $628.30, Change: $-69.95, Percent Change: -10.02%

$AIIR$REGN$STX
Asia Markets

US Equity Indexes Mixed, Crude Oil Rises as Iran Reportedly Sends Revised Peace Proposal

US equity indexes traded mixed as crude oil futures rose and government bond yields remained elevated after midday Monday amid reports of an updated peace proposal from Iran to end the war.The Nasdaq Composite fell 0.7% to 26,047.1, with the S&P 500 down 0.3% to 7,389.2. The Dow Jones Industrial Average rose 0.1% to 49,595.5.Technology and industrials led decliners intraday. Energy, financials, and communication services were among the top gainers.Iran has offered an updated proposal, which the White House sees as lacking meaningful improvement over the previous offer, rendering the latest version insufficient to reach a deal to end the war, a senior US official and a source briefed on the issue told Axios.However, a senior Iranian source told Reuters that the US had agreed to release a quarter of Iran's frozen funds - totaling tens of billions of dollars - held in foreign banks. The Iranian source also told the news agency that Washington has shown more flexibility in allowing Iran to continue some peaceful nuclear activity under the supervision of the International Atomic Energy Agency.Meanwhile, President Donald Trump is expected to meet top national security advisers on Tuesday to discuss options for resuming military action, Axios said in a separate news report. "The Clock is Ticking" for Iran, Trump said in a post on Truth Social at the weekend, adding that "they better get moving, FAST, or there won't be anything left of them. TIME IS OF THE ESSENCE!"West Texas Intermediate crude oil futures climbed 0.9% to $106.24, and Brent crude futures advanced 0.9% to $110.28.US Treasury yields traded mixed, but elevated. The 10-year was little changed at 4.6%, the highest since January 2025. The 30-year rate was steady at 5.13%, the strongest level since 2007.In precious metals, gold futures slipped 0.1% to $4,558.1, and silver futures were steady at $77.59.In economic news, the National Association of Home Builders' monthly housing market index rose to a reading of 37 in May from 34 in April, compared with expectations for a 34 print in a survey compiled by Bloomberg. The index was above the 34 print reported a year earlier."Recent increases for long-term interest rates will continue to hold back home buyer demand," said NAHB Chief Economist Robert Dietz. "Although some regional markets, including parts of the Midwest, are showing relative strength, the housing market continues to face significant affordability challenges."The New York Federal Reserve's services index improved to minus 5.8 in May from minus 14.0 in April, the highest level since January 2025. The index is the first services sector reading for May and suggests a slower contraction.In company news, NextEra Energy (NEE) and Dominion Energy (D) agreed to merge in an all-stock deal to create the world's largest regulated electric utility. Shares of Dominion jumped 8.8%, the second-biggest gainer on the S&P 500.Regeneron Pharmaceuticals' (REGN) miss on the fianlimab trial may lead some investors to question the company's broader strategy and execution, RBC Capital Markets said. Regeneron's shares sank 9.7%, the steepest decline on the S&P 500 and the Nasdaq.

Dow JonesNasdaq CompositeS&P 500$D$NEE$REGN
Research

Research Alert: CFRA Lowers Rating On Shares Of Regeneron Pharmaceuticals, Inc To Hold From Buy

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Shares of Regeneron are down more than 10% today after the company announced on Friday evening, after market close, that the Phase 3 study of fianlimab did not achieve a statistically significant primary endpoint in progression-free survival (PFS). The advanced clinical trials were assessing fianlimab in combination with cemiplimab (PD-1 inhibitor) for first-line unresectable or metastatic melanoma, a skin cancer that has spread beyond its original location versus pembrolizumab (PD-1 inhibitor), which is Merck's blockbuster oncology drug, Keytruda. While the company aims to present detailed data at an upcoming medical meeting, the release reflects diminished prospects for what had been anticipated as a highly promising treatment with a blockbuster potential, in our view. We lower our target price to $650 from $846, based on 12.4x our 2027 EPS estimate, a discount to REGN's 10-year historical forward P/E average. We retain our 2026 EPS estimate at $45.59 and our 2027 EPS estimate at $52.62.

$REGN
Wire

Canaccord Genuity Cuts Regeneron Pharmaceuticals Price Target to $875 From $1,057, Maintains Buy Rating

Regeneron Pharmaceuticals (REGN) has an average rating of overweight and mean price target of $839.77, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $630.74, Change: $-67.51, Percent Change: -9.67%

$REGN
Wire

Regeneron Pharmaceuticals Trial Miss May Raise Broader Strategy Questions, RBC Says

Regeneron Pharmaceuticals' (REGN) fianlimab trial miss might lead some investors to question the company's broader strategy and execution, RBC Capital Markets said.The company reported late Friday that two dose levels of fianlimab in combination with cemiplimab, evaluated as a first-line treatment in unresectable locally advanced or metastatic melanoma, failed to meet a primary endpoint in its phase 3 trial.RBC said the miss was disappointing as they had estimated peak worldwide probability-adjusted sales of about $1.6 billion to $1.8 billion for the drug, making it a meaningful setback for the company's pipeline.The investment firm said it does not see the miss as critical given several ongoing strengths, including continued strong growth from Dupixent, improving momentum for Eylea HD, expanded Dupixent lifecycle initiatives, and the expected increase in Sanofi (SNY) royalty contributions.The brokerage said this failure adds to a series of recent missteps, including the itepekimab setback, a less competitive launch label for Eylea HD, and manufacturing issues. Together, these events may lead some skeptics to question the company's overall direction."In short, near-miss is a tough break, and still there are lots of pipeline and other drivers, but disappointment in light of high expectations going in could raise bigger-picture questions," according to the note Sunday.RBC lowered its price target on Regeneron Pharmaceuticals to $707 from $762 while keeping its sector perform rating.Shares of Regeneron were down more than 10% in Monday trading.Price: $626.50, Change: $-71.76, Percent Change: -10.28%

$REGN
Sectors

Sector Update: Healthcare Stocks Decline Pre-Bell Monday

Healthcare stocks were declining pre-bell Monday, with the State Street Health Care Select Sector SPDR ETF (XLV) down 0.5% and the iShares Biotechnology ETF (IBB) 0.6% lower.Regeneron Pharmaceuticals (REGN) stock was down more than 11% after the company said two dose levels of fianlimab in combination with cemiplimab, evaluated as a first-line treatment in unresectable locally advanced or metastatic melanoma, failed to meet a primary endpoint in its phase 3 trial.Bio-Rad Laboratories (BIO) has attracted a sizable investment from Elliott Investment Management, which plans to push the life-science tools supplier to improve its lagging stock performance, The Wall Street Journal reported, citing people familiar with the matter. Bio-Rad Laboratories shares were up more than 7% premarket.Boston Scientific (BSX) entered into a $2 billion accelerated share repurchase agreement with JPMorgan Chase (JPM) as part of its previously announced $5 billion share buyback authorization, the company said. Boston Scientific also said it invested $1.5 billion for an approximately 34% stake in privately held MiRus. Shares of Boston Scientific were up about 2% pre-bell.

$BIO$BSX$IBB$JPM$REGN$XLV
Sectors

Sector Update: Health Care

Health care stocks were mixed pre-bell Monday, with the State Street Health Care Select Sector SPDR ETF (XLV) down 0.7% and the iShares Biotechnology ETF (IBB) 1.9% higher.Regeneron Pharmaceuticals (REGN) stock was down more than 12% after the company said two dose levels of fianlimab in combination with cemiplimab, evaluated as a first-line treatment in unresectable locally advanced or metastatic melanoma, failed to meet a primary endpoint in its phase 3 trial.

$REGN
Asia Markets

New Drone Incidents in Middle East Keep Tensions High, Nudge US Equity Futures Pre-Bell Lower

US equity futures were lower pre-bell Monday as tensions remain high in the Middle East after the UAE and Saudi Arabia reported fresh drone incidents on Sunday, raising traders' concerns around a return to hostilities in the region.Dow Jones Industrial Average futures were 0.3% lower, S&P 500 futures were down 0.2%, and Nasdaq futures were 0.1% lower.The UAE defense ministry said that a drone attack from the "western border" had caused a fire at a nuclear plant, while Saudi Arabia reported intercepting three drones that entered from the airspace of Iraq.President Donald Trump in a post on Truth Social urged Iran to "get moving" with regard to ending the conflict. "For Iran, the Clock is Ticking, and they better get moving, FAST, or there won't be anything left of them," he said.Among the companies reporting financial results this week are Home Depot (HD), Nvidia (NVDA), Analog Devices (ADI), and Walmart (WMT).Oil prices were lower, with front-month global benchmark North Sea Brent crude down 0.7% at $108.66 per barrel and US West Texas Intermediate crude 0.8% lower at $100.25 per barrel.The May US housing market index, slated for 10 am ET, is seen coming in at 34, unchanged from the prior month, according to estimates compiled by Bloomberg.Cheryl Venable, interim president of the Federal Reserve Bank of Atlanta, is slated to speak on Monday.In other world markets, Japan's Nikkei closed 1% lower, Hong Kong's Hang Seng ended 1.1% lower, and China's Shanghai Composite finished 0.1% lower. Meanwhile, the UK's FTSE 100 was up 0.5%, and Germany's DAX index was 0.8% higher in Europe's early afternoon session.In equities, Dominion Energy (D) shares jumped 15% after the company and NextEra Energy (NEE) said they agreed to combine in an all-stock deal. ServiceNow (NOW) stock was up 5.1% after the company and Experian said they launched a multiyear partnership on autonomous AI agents across various platforms. Baidu (BIDU) shares were up 4.2% after the company posted Q1 non-GAAP earnings and revenue that surpassed analysts' consensus.On the losing side, Tesla (TSLA) stock was down 0.9% after the company reportedly raised prices for several Tesla Model Y variants in the US, media outlets reported Saturday. Regeneron Pharmaceuticals (REGN) shares were 12% lower after the company said its phase 3 skin cancer trial evaluating two dose levels of fianlimab in combination with cemiplimab failed to meet a primary endpoint. NextEra Energy stock was down 1.3% after the merger with Dominion Energy was announced.

Dow JonesNasdaq CompositeS&P 500$ADI$BIDU$D$HD$NEE$NOW$NVDA$REGN$TSLA$WMT
Research

Leerink Partners Downgrades Regeneron Pharmaceuticals to Market Perform From Outperform, Adjusts PT to $641 From $792

Regeneron Pharmaceuticals (REGN) has an average rating of overweight and mean price target of $852.58, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$REGN
Research

Citigroup Downgrades Regeneron Pharmaceuticals to Neutral From Buy, Adjusts PT to $700 From $900

Regeneron Pharmaceuticals (REGN) has an average rating of overweight and mean price target of $852.58, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$REGN
Wire

Regeneron Fails to Meet Primary Endpoint in Phase 3 Skin Cancer Trial; Shares Down Pre-Bell

Regeneron Pharmaceuticals (REGN) said late Friday that two dose levels of fianlimab in combination with cemiplimab, evaluated as a first-line treatment in unresectable locally advanced or metastatic melanoma, failed to meet a primary endpoint in its phase 3 trial.The combination demonstrated a numeric 5.1-month improvement in median progression-free survival compared to pembrolizumab monotherapy, but did not reach statistical significance for the primary endpoint, Regeneron said.Regeneron said that detailed results from the trial will be presented at an upcoming medical meeting.A phase 3 head-to-head trial of the high-dose fianlimab combination compared with Opdualag is ongoing, the company added.Shares of the company were down more than 11% in Monday's premarket activity.Price: $616.00, Change: $-82.25, Percent Change: -11.78%

$REGN
Wire

Regeneron's Eylea Franchise on 'Solid Footing' Despite HD Sales Miss in Q1, Oppenheimer Says

Regeneron Pharmaceuticals' (REGN) Q1 results reflected mixed trends, as weaker-than-expected sales of high-dose Eylea weighed on shares, though the broader franchise remains "on solid footing," Oppenheimer said in a note Wednesday.The biotechnology company posted non-GAAP earnings of $9.47 per diluted share, surpassing analyst expectations, but the stock faced downward pressure after Eylea HD recorded $468 million in sales, below the $490 million consensus, the brokerage said.The Eylea franchise got a boost with the US Food and Drug Administration approval of "extended dosing" intervals for HD in wet age-related macular degeneration and diabetic macular edema, according to the note. A decision on a pre-filled syringe is expected in Q2 and Oppenheimer said label expansion for HD could support adoption and help offset market share pressure.Dupixent remains a "key growth driver," supported by "durable demand" and new indications, including chronic spontaneous urticaria and allergic fungal rhinosinusitis, according to the note.Despite competition, the company's outlook is balanced, supported by Dupixent growth, expanding Eylea HD uptake, and expected higher collaboration profits with Sanofi (SNY), the brokerage said.Oppenheimer maintained an outperform rating on Regeneron, with a price target of $865.Shares of Regeneron were up more than 3% in Thursday trading.Price: $707.76, Change: $+21.40, Percent Change: +3.12%

$REGN$SNY
Wire

Raymond James Adjusts Regeneron Pharmaceuticals Price Target to $902 From $910

Regeneron Pharmaceuticals (REGN) has an average rating of overweight and mean price target of $880.77, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $705.61, Change: $+19.25, Percent Change: +2.80%

$REGN
Wire

Leerink Partners Adjusts Regeneron Pharmaceuticals Price Target to $792 From $873

Regeneron Pharmaceuticals (REGN) has an average rating of overweight and mean price target of $880.77, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $705.61, Change: $+19.25, Percent Change: +2.80%

$REGN
Wire

Barclays Adjusts Regeneron Pharmaceuticals Price Target to $917 From $923

Regeneron Pharmaceuticals (REGN) has an average rating of overweight and mean price target of $880.77, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $705.61, Change: $+19.25, Percent Change: +2.80%

$REGN
Wire

Morgan Stanley Adjusts Regeneron Pharmaceuticals PT to $788 From $796

Regeneron Pharmaceuticals (REGN) has an average rating of overweight and mean price target of $880.77, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $705.61, Change: $+19.25, Percent Change: +2.80%

$REGN
Wire

Goldman Sachs Adjusts Regeneron Pharmaceuticals Price Target to $968 From $967

Regeneron Pharmaceuticals (REGN) has an average rating of overweight and mean price target of $880.77, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $706.67, Change: $+20.31, Percent Change: +2.96%

$REGN

Showing 1-20 of 34